Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000034251
JPRN-UMIN000034251
Completed
未知

Prediction of the pharmacokinetics and adverse events of glecaprevir/pibrentasvir in patients with hepatitis C virus by gadoxetic acid enhanced magnetic resonance imaging - Prediction of the PKs and AEs of GLE/PIB by EOB-MRI

Juntendo University Nerima Hospital0 sites60 target enrollmentSeptember 25, 2018
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsType C chronic hepatitis or type C liver cirrhosis

Overview

Phase
未知
Intervention
Not specified
Conditions
Type C chronic hepatitis or type C liver cirrhosis
Sponsor
Juntendo University Nerima Hospital
Enrollment
60
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 25, 2018
End Date
June 30, 2021
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •1\) Hypersensitivity to Gd\-EOB\-DTPA 2\) Estimated glomerular filtration rate under 40ml/min/1\.73m2

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Prediction of the pharmacokinetics and adverse events of nab-paclitaxel in patients with pancreatic cancer by magnetic resonance imagingnresectable locally advanced pancreatic cancer or metastatic pancreatic cancer
JPRN-UMIN000026180Juntendo University40
Completed
Not Applicable
Prediction of the pharmacokinetics and adverse events of paritaprevir in patients with hepatitis C virus by magnetic resonance imagingType C chronic hepatitis or type C liver cirrhosis
JPRN-UMIN000022587Juntendo University Nerima Hospital Department of Gastroenterology30
Active, not recruiting
Phase 1
Metabolism and effects of naloxone given as a spray in healthy volunteers and children.Sedation after opioid administrationPharmacokinetic profile after naloxone administered intranasallyTherapeutic area: Body processes [G] - Physical Phenomena [G01]
EUCTR2013-005201-31-SEKarolinska University Hospital20
Recruiting
Phase 1
Phase 1 study of 211At-MABG in patients with pheochromocytoma/pargangliomaPheochromocytoma, paragangliomaD010673, D010235
JPRN-jRCT2021220012Shiga Tohru18
Completed
Not Applicable
Study of blood level of lifesaving antibiotic meropenum in serious ICU patients in relation to blood level that kills bacteria.
CTRI/2013/07/003850Tata Memorial Hospital25